The current results confirmed our earlier report of over-expression of PRAME, CTAG1 and CTAG2 in liposarcomas using the U_95 array [7] with the newer U_133 array, and also demonstrated that the expression of these potential targets of immunotherapy is heterogeneous among STS. The gene discussed is PRAME; the disease is telomere syndrome.